Antioxidants inhibit the in vitro production of inflammatory cytokines in Crohn's disease and ulcerative colitis

European Journal of Clinical Investigation

Volumn 28, Issue 2, 1998, Pages 145-150

  Reimund, J M ^a,b,c,h   Allison, A C ^d   Muller, C D ^e,i   Dumont, S ^a,h   Kenney, J S ^e,f,g,i   Baumann, R ^b   Duclos, B ^b,c   Poindron, P ^a,h  

^a Illkirch Graffenstaden   (France)

^b HÔPITAL DE HAUTEPIERRE   (France)

^c INSERM   (France)

^d DAWA Inc   (United States)

^e U de Recherche CNRS URA 491   (France)

^f Antibody Solutions   (United States)

^g URA 491 du CNRS

^h Dept d'Immunol I   (France)

ⁱ Laboratoire de Biophysique   (France)

Author keywords

Antioxidants; Crohn's disease; Cytokines; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

ANTIOXIDANT; BUTYLATED HYDROXYANISOLE; CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; NORDIHYDROGUAIARETIC ACID; TETRAHYDROPAPAVEROLINE;

ADULT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; COLON BIOPSY; COLON MUCOSA; CROHN DISEASE; CYTOKINE RELEASE; ENTERITIS; HUMAN; MONONUCLEAR CELL; PRIORITY JOURNAL; ULCERATIVE COLITIS;

ADULT; ANTIOXIDANTS; BUTYLATED HYDROXYANISOLE; CELL-FREE SYSTEM; CELLS, CULTURED; COLITIS, ULCERATIVE; CROHN DISEASE; CYTOKINES; DIMETHYL SULFOXIDE; HUMANS; INTESTINAL MUCOSA; LEUKOCYTES, MONONUCLEAR; MIDDLE AGED; NORDIHYDROGUAIARETIC ACID; ORGAN CULTURE TECHNIQUES;

EID: 0031951719     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1998.00257.x     Document Type: Article

References (31)

1. Sartor RB. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Gastroenterotogical Clinics of North America, 1995; 24: 475-508.
2. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumor necrosis factor-alpha, IL-6 and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clinical and Experimental Immunology, 1993; 94: 174-81.
3. Reimund JM, Wittersheim C, Dumont S, et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease, Journal of Clinical Immunology, 1996; 16: 144-50.
4. Simmonds MJ, Rampton DS. Inflammatory bowel disease - a radical view. Gut, 1993; 34: 865-8.
5. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1. EMBO Journal, 1991; 10: 2247-58.
6. Baeuerle PA, Henkel T. Function and activation of NF-κB in the immune system. Annual Review of Immunology, 1994; 12: 141-79.
7. Chaudhri G, Clark IA. Reactive oxygen species facilitate the in vitro and in vivo lipopolysaccharide-induced release of tumor necrosis factor. Journal of Immunology, 1989; 143: 1290-4.
8. Eugui EM, DeLustro B, Rouhafza S, et al. Some antioxidants inhibit, in a coordinate fashion, the production of tumor necrosis factor-α, IL-1β, and IL-6 by human peripheral blood mononuclear cells. International Immunology, 1994; 6: 409-22.
9. Peristeris P, Clark BD, Gatti S, et al. N-acetylcysteine and glutathione as inhibitors of tumor necrosis factor production. Cellular Immunology, 1994; 140: 390-9.
10. Akeson AL, Woods CW, Mosher LB, Thomas CE, Jackson RL. Inhibition of IL-1β expression in THP-1 cells by probucol and tocopherol. Atherosclerosis, 1991; 86: 261-70.
11. Lennard-Jones JE. Definition and Diagnosis in Regional Enteritis. Skandia International Symposium Nordiska, Stockholm, 1971; 105-16.
12. Van Hees PAM, Van Elteren PH, Van Lier HJJ, Van Tongeren JHM. An index of inflammatory activity in patients with Crohn's disease. Gut, 1980; 21: 279-86.
13. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. British Medical Journal, 1955; 2: 1041-8.
14. Bøyum A. Isolation of mononuclear cells and granulocytes from human blood. Scandinavian Journal of Laboratory Investigation, 1968; 21: 77-89.
15. Wardle TD, Hall L, Turnberg LA. Use of coculture of colonic mucosal biopsies to investigate the release of eicosanoids by inflamed and uninflamed mucosa from patients with inflammatory bowel disease. Gut, 1992; 33: 1644-51.
16. Kenney JS, Masada MP, Eugui EM, Delustro BM, Mulkins BA, Allison AC. Monoclonal antibodies to human recombinant interleukin 1 (IL-1) β: quantification of IL-1β and inhibition of biological activity, Journal of Immunology, 1987; 138: 4236-42.
17. Neuner P, Klosner G, Schauer E, et al. Pentoxifylline in vivo down-regulates the release of IL-1β, IL-6, IL-8 and tumor necrosis factor-α by human peripheral blood mononuclear cells. Immunology, 1994; 83: 262-7.
18. Reimund JM, Dumont S, Muller CD, et al. In vitro effects of oxpentifylline on inflammatory cytokine production in patients with inflammatory bowel disease. Gut, 1997; 40: 475-80.
19. Targan S, Rutgeerts P, Hanauer SB, et al. A multicenter trial of anti-tumor necrosis factor (TNF) antibody (cA2) for treatment of patients with active Crohn's disease (abstract). Gastroenterology, 1996; 110: A1026.
20. Von Ritter C, Grisham MB, Hollwarth M, Inauen W, Granger DN. Neutrophil-derived oxidants mediate formyl-methionyl-leucyl-phenylalanine-induced increases in mucosal permeability in rats. Gastroenterology, 1989; 97: 778-80.
21. Keshavarzian A, Haydek J, Zabihi R, Doria M, D'Astice M, Sorenson JRJ. Agents capable of eliminating reactive oxygen species. Digestive Diseases and Sciences, 1992; 37: 1866-1673.
22. Gross V, Arndt H, Andus K, Palitzsch KD, Schölmerich J. Free radicals in inflammatory bowel diseases. Pathophysiology and therapeutic implications. Hepato-Gastroenterology, 1994; 41: 320-7.
23. Yoshikawa T, Takahashi S, Kondo M. Possible role of free radicals in the chronic inflammation of the gut. EXS, 1992; 62: 353-358.
24. Moyana T, Lalonde JM. Carrageenan-induced intestinal injury: possible role of oxygen free radicals. Annals of Clinical Laboratory Science, 1991; 21: 258-63.
25. Mazlam MZ, Montazeri G, Hodgson JF. The effects of some anti-inflammatory agents on cytokine release from human monocytes in vitro. European Journal of Gastroenterology and Hepatology, 1993; 5: 515-20.
26. Mahida YR, Lamming CED, Gallagher A, Hawthorne AB, Hawkey CJ. 5-Aminosalicylic acid is a potent inhibitor of interleukin 1β production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut, 1991; 32: 50-4.
27. Rachmilewitz D, Karmeli F, Schwanz LW, Simon OL. Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin1 generation. Gut, 1992; 33: 929-32.
28. Simmonds NJ, Allen RE, Stevens TR, Van Someren RNM, Blake DR, Rampton DS. Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease. Gastroenterology, 1992; 103: 186-96.
29. Emerit J, Pelletier S, Tosoni-Verligue D, Mellet M. Phase II trial of copper zinc superoxide dismutase (CuZn-SOD) in the treatment of Crohn's disease. Journal of Free Radical Biology and Medicine, 1989; 7: 145-50.
30. Levin KE, Pemberton JH, Philipps SF, Zinsmeister AR, Pezim ME. Role of oxygen free radicals in the aetiology of pouchitis. Diseases of the Colon and Rectum, 1992; 35: 452-6.
31. Salim AWSS. Role of oxygen-derived free radical scavengers in the management of recurrent attacks of ulcerative colitis: a new approach. Journal of Laboratory Clinical Medicine, 1992; 119: 710-17.